Summary basis of decision for INLYTA™

Health Canada has issued a Notice of Compliance to Pfizer Products Inc., for the drug product Inlyta. Inlyta contains the medicinal ingredient axitinib which is a kinase inhibitor and an anti-tumour agent. Inlyta is indicated for the treatment of patients with metastatic renal cell carcinoma (RCC) of clear cell histology after failure of prior systemic therapy with either a cytokine or the vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitor (TKI), sunitinib. Read more here.